“Prospective, randomized, multicenter study to compare the efficacy at 52 weeks (1 year) of biosimilar teriparatide and alendronate in the prevention of new morphometric vertebral fractures and/or aggravation of previous vertebral fractures in women with clinical vertebral fracture or recent hip fracture (imminent risk of fracture) and low bone mineral density. IMMINENT Study
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: GEDEON RICHTER IBÉRICA SA
- Phase: IV
- Execution start: 14/06/2022
- End of execution: 30/12/2023
- PI: ENRIQUE RAYA ALVAREZ